Mobile ECG camps across rural Kerala now detect atrial fibrillation in villagers who might otherwise never have been tested. What happens after the tracing is printed is the contested part. Detection is cheap and portable; the treatment that prevents strokes is neither, and the gap between them has split cardiologists and public health researchers over whether this screening should continue at its present scale.

The Screening Van in Wayanad

Wayanad is Kerala's hill district, a landscape of tea estates, tribal hamlets and roads that turn to slurry in the monsoon. Reaching a district hospital can take an hour or more from the outer settlements, and specialist cardiology sits further away still. Into that gap have driven screening vans equipped with single-lead ECG devices, run by charitable trusts and district health programmes, offering a free heart rhythm check at village squares and primary health centres.

The pitch is straightforward. Atrial fibrillation is common, often silent, and a major contributor to ischaemic stroke. Find it early, start an anticoagulant, prevent the stroke. Screening camps are reported in local coverage as straightforward successes, measured in hundreds of villagers checked and dozens of irregular rhythms flagged.

What the coverage rarely follows is the second half of that sentence. A flagged tracing is a suspicion, not a diagnosis. The confirmatory twelve-lead ECG, the cardiology opinion, the baseline bloods and the ongoing drug supply all sit downstream, and in Wayanad's outer panchayats they are not reliably there. This site has reported a similar pattern with hypertension in Brazil's northeast, where the diagnosis arrives after the stroke rather than before it: diagnoses arriving after the stroke.

What the Detectors Actually Find

Atrial fibrillation is an irregular, often rapid rhythm that begins as short episodes and tends to lengthen over time. Its prevalence climbs steeply with age, which matters in Kerala more than in most Indian states: the state has the country's oldest population profile, with a large share of residents over sixty. A screening camp in a district like Wayanad is fishing in water where the condition is genuinely common.

The devices themselves create a second problem. Single-lead tracings are good at flagging irregularity and poor at distinguishing atrial fibrillation from atrial flutter, frequent premature beats, or brief paroxysmal episodes that may never recur. A ten-second strip cannot tell you whether the rhythm was sustained. Artefact from a shaky hand or a loose electrode can mimic irregularity convincingly.

Without a twelve-lead confirmation, a proportion of camp positives will be false. Some will be true atrial fibrillation of low stroke risk. Others will be transient episodes whose significance is genuinely uncertain. The camp number that gets reported is detections, not confirmed diagnoses, and the two are not the same figure.

The Anticoagulation Gap

Stroke prevention in atrial fibrillation means anticoagulation, and in rural Kerala that means a choice between two imperfect options. Warfarin is cheap but demands regular INR monitoring, which requires a coagulation laboratory and a reliable return visit. Direct oral anticoagulants need no monitoring but cost money that most households in this belt do not have spare, month after month, indefinitely.

Primary health centres in the district generally lack coagulation testing on site. A patient on warfarin may need to travel to a taluk or district facility for each check, and the checks are frequent early on. When the journey is long and the transport unreliable, monitoring lapses, and unmonitored warfarin is a bleeding risk rather than a protection.

Stroke risk scores such as CHA2DS2-VASc were built and validated on untreated or variably treated populations. Applying them to a screening camp cohort, where many patients will never actually start or sustain therapy, produces a risk estimate that does not describe what will happen to these particular people. The score assumes the treatment decision follows. In Wayanad, often it does not.

The Cost of a False Positive

The economics of a camp are usually presented as a bargain: a device, a trained technician, a few hours in a village hall. That arithmetic stops at the tracing. Every positive generates a confirmatory ECG, a consultation, baseline renal and liver function, a bleeding risk assessment, and then a drug decision. Multiply that across the dozens of flags a busy camp produces and the downstream cost dwarfs the cost of detection.

That cost does not disappear because the camp was free. It lands on the household, in travel, lost wages and consultation fees, or it lands nowhere and the patient is simply lost. A programme that budgets for the van and not for the follow-up has not saved the health system money; it has moved the spending to a place where nobody is counting it, or has avoided the spending altogether and left the stroke to happen.

There is a version of this that is defensible. Where a camp can hand a patient a booked appointment, a confirmed diagnosis and a secured drug supply, the downstream cost is an investment with a measurable return in strokes avoided. The difference between the two versions is not the device. It is whether anyone has costed the whole pathway before printing the first tracing.

The Case Against Blanket Screening

The strongest objection is evidential. No trial has shown that screening for atrial fibrillation reduces stroke rates at population level. The trials that exist show that screening increases detection, which is a different outcome. Detection without sustained treatment moves the number that gets counted and leaves the number that matters where it was.

There is a harm on the other side too. Anticoagulation in older patients carries a real bleeding risk, including intracranial haemorrhage, and that risk is highest in exactly the frail elderly patients most likely to test positive at a village camp. Overdiagnosis of brief, self-limiting episodes commits some of these patients to a drug they did not need, with a risk they now carry.

Against that, opportunistic pulse checks are already standard practice in many consultations, and a pulse check costs nothing. The question is not whether to look for atrial fibrillation. It is whether a van, a device and a printed tracing add anything to a GP's finger on a radial artery when the treatment pathway behind both is equally thin.

Where Reasonable Experts Split

Cardiologists who favour early detection point to the rhythm-control argument: identifying atrial fibrillation sooner allows earlier intervention, and untreated atrial fibrillation tends to progress. They see the camps as a reasonable first step, with the treatment gap a solvable logistics problem rather than a reason to stop looking.

Public health researchers counter that logistics is the whole problem. A screening programme is a system, not a device, and judging it by the device's performance is a category error. They want pragmatic trials run in Kerala's own districts, measuring stroke incidence and treatment initiation, not detection counts. Cost-effectiveness analysis turns entirely on local stroke incidence and on drug prices, both of which vary enough that imported estimates mislead.

Kerala's ageing profile sharpens the stakes on both sides. The state will have more atrial fibrillation to find every year for the next two decades. Whether it finds it through camps or through strengthened primary care is a decision that will shape stroke burden for a generation, and it is being made largely by default.

Making Screening Worth Doing

Pair every ECG camp with a booked confirmatory appointment, so that a flagged tracing produces a scheduled twelve-lead ECG and a clinical review rather than a piece of paper and advice to seek care. A camp that cannot guarantee the follow-up slot should not run.

Budget the anticoagulant before buying the device. A district programme that can supply warfarin with reliable INR access, or subsidise a direct oral anticoagulant, is doing more for stroke prevention than one that adds another screening van to the fleet.

Train ASHA workers to perform and interpret pulse checks during routine household visits, and give them a clear referral route for an irregular finding. This site has described community health workers catching newborn sepsis where laboratories cannot: health workers catching sepsis. The same logic applies to a pulse.

Report detection and treatment initiation as a single figure, so that a camp's success is measured by patients actually anticoagulated at six months rather than by tracings collected on the day.

Fund pragmatic trials in Kerala's own districts, with stroke incidence as the endpoint, so that the next round of screening policy rests on local evidence rather than on extrapolation from elsewhere. The related question of how health systems ration older drugs when newer ones are unaffordable is taken up in treating infections with older drugs.

This article is informational and does not constitute personalised medical advice. Anyone with a detected irregular rhythm should discuss confirmation and treatment with a qualified clinician.